{"id":"madopar-monotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Hallucinations"}]},"_chembl":{"chemblId":"CHEMBL5220637","moleculeType":null,"molecularWeight":"454.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine in the central nervous system. Benserazide is a peripheral decarboxylase inhibitor that prevents levodopa from being converted to dopamine outside the brain, thereby increasing the amount of levodopa available for central conversion and reducing peripheral side effects. This combination allows lower doses of levodopa to be effective while minimizing gastrointestinal and cardiovascular adverse effects.","oneSentence":"Madopar combines levodopa and benserazide to increase dopamine levels in the brain by delivering levodopa across the blood-brain barrier while benserazide blocks its peripheral conversion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:39.347Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT04968613","phase":"PHASE4","title":"Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2018-01-01","conditions":"Parkinson Disease, Memory Impairment","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Madopar monotherapy","genericName":"Madopar monotherapy","companyName":"Peking University Third Hospital","companyId":"peking-university-third-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Madopar is a combination of levodopa and benserazide that increases dopamine levels in the brain by providing the dopamine precursor while inhibiting its peripheral metabolism. Used for Parkinson's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}